Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies

作者：Ishida Takashi; Utsunomiya Atae; Jo Tatsuro; Yamamoto Kazuhito; Kato Koji; Yoshida Shinichiro; Takemoto Shigeki; Suzushima Hitoshi; Kobayashi Yukio; Imaizumi Yoshitaka; Yoshimura Kenichi; Kawamura Kouichi; Takahashi Takeshi; Tobinai Kensei; Ueda Ryuzo

来源：CANCER SCIENCE, 2017, 108(10): 2022-2029.

DOI：10.1111/cas.13343

• Adult T-cell leukemia-lymphoma
• CC chemokine receptor 4
• mogamulizumab
• rash
• regulatory T cell

The present study sought to elucidate the prognosis of adult T-cell leukemia-lymphoma (ATL) patients receiving mogamulizumab, a defucosylated anti-CCR4 monoclonal antibody. Progression-free survival (PFS) and overall survival (OS) of ATL patients enrolled in two studies are herein updated, namely NCT00355472 (phase I study of mogamulizumab in relapsed patients with ATL and peripheral T-cell lymphoma) and NCT00920790 (phase II study for relapsed ATL). Of 13 patients with relapsed aggressive ATL in the phase I study, four (31%) survived >3 years. For 26 relapsed patients with aggressive ATL in the phase II study, median PFS was 5.2 months and 1-year PFS was 26%, whereas median OS was 14.4 months, and 3-year OS was 23%. For patients without a rash or who developed a grade 1 rash only, median PFS was 0.8 months, and 1-year PFS was zero, with a median OS of 6.0 months, and 3-year OS of 8%. In contrast, for patients who developed a rash grade 2, median PFS was 11.7 months, and 1-year PFS was 50%, with a median OS of 25.6 months, and 3-year OS of 36%. Thus, we conclude that mogamulizumab monotherapy may improve PFS and OS in some patients with relapsed aggressive ATL, especially those who develop a skin rash as a moderate immune-related adverse event. Therefore, further investigation is warranted to validate the present observations and to clarify the mechanisms involved in the activity of mogamulizumab.

• 出版日期2017-10